Ibrutinib-induced Sweet syndrome.

Noor Almaani, Zain Al Ta'ani, Maram Abdaljaleel, Faris AlShammas, Alaa Alshorman

Abstract readCase Reports

In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Noor AlmaaniDepartment of Dermatology, School of Medicine, University of Jordan, Amman, Jordan. n.almaani@ju.edu.jo.

Zain Al Ta'aniDepartment of Dermatology, School of Medicine, University of Jordan, Amman, Jordan.

Maram AbdaljaleelDepartment of Pathology, Microbiology and Forensic Medicine, School of Medicine, University of Jordan, Amman, 11942, Jordan.

Faris AlShammasDepartment of Pathology, Microbiology and Forensic Medicine, School of Medicine, University of Jordan, Amman, 11942, Jordan.

Alaa AlshormanHematology Department, Al Basheer Hospital, Ministry of Health, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ibrutinib is an oral targeted drug that has been approved by the US Food and Drug Administration (FDA) for the management of chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia, and previously treated chronic graft-versus-host disease. It is an irreversible selective inhibitor of Bruton's tyrosine kinase (Btk)1. We report the case of a 54-year-old male patient, diagnosed with CLL being who was with ibrutinib. He developed several erythematous and indurated plaques on the neck, face, hands, and scalp, 8 months into his treatment. Clinical features along with skin biopsy findings of a neutrophil predominant infiltrate were consistent with the diagnosis of Sweet syndrome. Upon withdrawal of the medication and application of a potent topical steroid, cutaneous lesions healed after one week. However, readministration of the medication at a lower dose was associated, with recurrence of the lesions, suggesting a temporal relationship with ibrutinib and necessitating drug discontinuation.

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsPyrazolesPyrimidinesSweet SyndromeAdenineHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPiperidinesAdenineAntineoplastic AgentsibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesDrug-induced cutaneous side effectIbrutinibNeutrophilic dermatosis

Identifiers

PMID42101632

DOI10.1007/s00210-026-05399-2

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.